These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31106203)

  • 21. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
    Younossi ZM; Stepanova M; Nader F; Loomba R; Anstee QM; Ratziu V; Harrison S; Sanyal AJ; Schattenberg JM; Barritt AS; Noureddin M; Bonacci M; Cawkwell G; Wong B; Rinella M;
    Clin Gastroenterol Hepatol; 2022 Sep; 20(9):2050-2058.e12. PubMed ID: 34274514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review.
    Grønkjær LL; Lauridsen MM
    JHEP Rep; 2021 Dec; 3(6):100370. PubMed ID: 34805816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
    Vali Y; Lee J; Boursier J; Petta S; Wonders K; Tiniakos D; Bedossa P; Geier A; Francque S; Allison M; Papatheodoridis G; Cortez-Pinto H; Pais R; Dufour JF; Leeming DJ; Harrison SA; Chen Y; Cobbold JF; Pavlides M; Holleboom AG; Yki-Jarvinen H; Crespo J; Karsdal M; Ostroff R; Zafarmand MH; Torstenson R; Duffin K; Yunis C; Brass C; Ekstedt M; Aithal GP; Schattenberg JM; Bugianesi E; Romero-Gomez M; Ratziu V; Anstee QM; Bossuyt PM;
    Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):714-725. PubMed ID: 36958367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment.
    Aggio D; Gallop K; Wittrup-Jensen V; Farsani SF; Lloyd AJ
    J Comp Eff Res; 2024 Feb; 13(2):e230033. PubMed ID: 38226909
    [No Abstract]   [Full Text] [Related]  

  • 27. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
    Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
    Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
    JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
    J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study on the correlation between type 2 diabetes mellitus combined with non-alcoholic steatohepatitis and aerobic exercise performance].
    Zhang J; Li L; Yu HY; Li Y; Wang FM; Di FS
    Zhonghua Gan Zang Bing Za Zhi; 2023 Oct; 31(10):1068-1074. PubMed ID: 38016772
    [No Abstract]   [Full Text] [Related]  

  • 34. The Role of Web-Based Adaptive Choice-Based Conjoint Analysis Technology in Eliciting Patients' Preferences for Osteoarthritis Treatment.
    Al-Omari B; Farhat J; Shraim M
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review.
    Kennedy-Martin T; Bae JP; Paczkowski R; Freeman E
    J Patient Rep Outcomes; 2017; 2():28. PubMed ID: 29984351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?
    Wessels DH; Rosenberg Z
    World J Hepatol; 2021 Feb; 13(2):233-241. PubMed ID: 33708352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T
    Hepatol Res; 2015 Apr; 45(4):363-77. PubMed ID: 25832328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.